What is DiscGenics?
DiscGenics is a clinical-stage biotechnology firm focused on the development of innovative regenerative therapies designed to restore function and alleviate pain in patients with degenerative spinal diseases. The company's flagship product candidate, IDCT, utilizes allogeneic, injectable Discogenic Cells—specialized progenitor cells engineered to address the biological complexities of the intervertebral disc. By shifting the paradigm from symptomatic management to regenerative intervention, DiscGenics occupies a critical niche in the musculoskeletal health market. Their approach aims to provide a non-surgical alternative for millions of individuals, effectively bridging the gap between conservative pain management and invasive spinal surgery.
How much funding has DiscGenics raised?
DiscGenics has raised a total of $71.9M across 5 funding rounds:
Series A
$7M
Series B
$14M
Debt
$350K
Series C
$50M
Debt
$562K
Series A (2013): $7M, investors not publicly disclosed
Series B (2017): $14M led by Mitsubishi Corporation
Debt (2020): $350K supported by PPP
Series C (2020): $50M featuring CareNet of Japan, Eagle Private Capital LLC, Ci:z Holdings Co. Ltd., Medical Incubator Japan K.K, and Mitsubishi UFJ Capital Co. Ltd
Debt (2021): $562K backed by PPP
Key Investors in DiscGenics
Mitsubishi Corporation
A global integrated business enterprise that operates across diverse sectors including industrial finance, energy, and healthcare infrastructure.
Medical Incubator Japan K.K
A specialized venture capital firm focused on supporting the growth of innovative medical technology and biotechnology companies in Japan.
Eagle Private Capital LLC
A private equity firm providing capital and strategic support to middle-market companies across various industries, including healthcare and life sciences.
What's next for DiscGenics?
With the support of its recent strategic financing, DiscGenics is poised to advance its clinical trial programs and scale its manufacturing capabilities to meet anticipated market demand. The company's strategic roadmap emphasizes the validation of its cell therapy platform through rigorous clinical data, which will be essential for regulatory approval and subsequent commercialization. As the firm transitions into more advanced stages of development, it will likely focus on expanding its intellectual property portfolio and strengthening its partnerships with global healthcare entities. The current capital position provides the necessary runway to navigate the complexities of late-stage clinical trials, ensuring that the company remains at the forefront of the regenerative medicine revolution.
See full DiscGenics company page
